$OVID

Ovid Therapeutics (OVID) reported Q2 results with $169.8M cash, funding operations into 2029. Progress on OV4071 and OV329 clinical trials. R&D expenses rose to $10M, net loss widened to $15M. Soticlestat deal brings potential $294.5M in milestones and royalties. Share count increased after warrant exercises.

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

BlackRock, Inc. filed a Schedule 13G reporting beneficial ownership of 10,822,672 shares of Ovid Therapeutics Inc. common stock, or 5.8% of the outstanding class, as of June 30, 2026. The filing states sole voting power of 10,707,787 shares and sole dispositive power of 10,822,672 shares.

B. Riley reiterated a Buy rating on Ovid Therapeutics, Inc. after meeting CEO Meg Alexander. The firm cited catalysts for OV329 and KCC2 between year-end 2026 and early 2027, including open-label PPR topline data and ketamine challenge data, and said cash extends funding into 2029. Ovid reported Q1 results in line with expectations and dosed the first OV4071 participant.

Ovid Therapeutics (NASDAQ:OVID) said it appointed Kevin Norrett as chief business officer to lead business development and partnerships, promoted Charles Carter to CFO, and elevated Victoria Fort to chief strategy officer. The company also noted Q1 EPS of -12c versus -11c consensus and expects funding into 2029, citing pipeline progress.

Ovid Therapeutics (Nasdaq: OVID) announced executive leadership changes to support its pipeline. Kevin Norrett will become Chief Business Officer, Charles Carter promoted to CFO, Eliseo Salinas joins as Executive R&D Advisor, and Victoria Fort promoted to Chief Strategy Officer. The company cited ongoing development of OV329 and KCC2 activators and said cash runway extends into 2029.

Ovid Therapeutics Inc. (OVID) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ovid-20260707 0001636651 false 0001636651 2024-03-08 2024-03-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Ovid Therapeutics Inc. (OVID) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. ovid-20260611 0001636651 false 0001636651 2024-03-08 2024-03-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Ovid Therapeutics has secured $60 million in investment to further its work on seizure drugs, marking its second private investment in public equity (PIPE) deal in recent months. This funding highlights continued investor interest in the company's pharmaceutical developments. The article also touches on other business news, including strong Manhattan luxury home sales and changes in New York's outdoor dining policies.

Ovid Therapeutics Inc. filed its annual report on Form 10-K, detailing its biopharmaceutical focus on small molecule medicines for brain disorders. The company highlights its lead programs, OV329 for drug-resistant epilepsies and OV4071 as a KCC2 direct activator for psychoses and mood disorders, with clinical trials for both underway or planned. Ovid also discusses its financial position, ongoing operating losses, and recent private placement financings to support its research and development pipeline.